Sonoma Pharmaceuticals, Inc.(SNOA)Earnings, Financials & Key Ratios
SNOA•NASDAQ
$1.18
$2M mkt cap·Price updated May 7, 2026
AboutSonoma Pharmaceuticals, Inc., develops and produces stabilized hypochlorous acid (HOCl) products for wound care, animal health care, eye care, oral care, and dermatological conditions in the United States, Latin America, Europe, and internationally. The company offers Epicyn, an antimicrobial facial cleanser; Levicyn, an HOCl based prescription product to manage and relieve burning, itching, and pain experienced with various types of dermatoses; Celacyn gel, a HOCl-based topical prescription product indicated to promote efficient healing through the management of new and old scars; and SebuDerm to manage and relieve the burning, itching, erythema, scaling, and pain associated with seborrhea and seborrheic dermatitis. It also provides Acuicyn, a HOCl-based product indicated to relieve itch and inflammation while helping to keep areas around the eye clean; and Microcyn, a HOCl-based topical line of products designed to stimulate expedited healing by targeting a wide range of pathogens, as well as antibiotic-resistant strains that slow the natural healing of wounds. In addition, the company offers MicrocynAH, an HOCl-based solution designed to relieve common symptoms of hot spots, scratches, skin rashes post-surgical sites, and irritated animal skin for healing; Microdacyn60 oral care solution for the treatment of mouth and throat infections; MucoClyns for the use in emergencies and safe to use on mucous membranes, cuts, abrasions, burns, and body surfaces; Endocyn root canal irrigation solutions; Pediacyn atopic dermatitis hydrogel; Ocucyn eyelid and eyelash cleanser; Gramaderm for the treatment of topical mild to moderate acne; Nanocyn, a hospital-grade disinfectant; and Sinudox for nasal irrigation. The company was formerly known as Oculus Innovative Sciences, Inc. and changed its name to Sonoma Pharmaceuticals, Inc. in December 2016. Sonoma Pharmaceuticals, Inc. was incorporated in 1999 and is based in Woodstock, Georgia.Show more
- Revenue$14M+12.2%
- EBITDA-$4M+21.1%
- Net Income-$3M+28.5%
- EPS (Diluted)-2.79+47.6%
- Gross Margin38.25%+2.7%
- EBITDA Margin-25%+29.6%
- Operating Margin-25.97%+29.7%
- Net Margin-24.2%+36.3%
- ROE-65.55%+4.3%
- ROIC-188.07%-130.0%
- Debt/Equity0.07-30.2%
SNOA Key Insights
Sonoma Pharmaceuticals, Inc. (SNOA) fundamental analysis — strengths, weaknesses & financial health based on data analysis
✓Strengths
- ✓Company is almost debt free
- ✓Trading at only 0.3x book value
- ✓Efficient asset utilization: 1.0x turnover
✗Weaknesses
- ✗Negative free cash flow
- ✗Weak momentum: RS Rating 2 (bottom 2%)
- ✗Low quality earnings: Net income not backed by cash flow
- ✗Shares diluted 36.5% in last year
- ✗Trading more than 30% below 52-week high
* These insights are generated automatically based on available financial data. Please conduct your own research before making investment decisions.
SNOA Price & Volume
Sonoma Pharmaceuticals, Inc. (SNOA) stock price & volume — 10-year historical chart
Loading chart...
SNOA Growth Metrics
Sonoma Pharmaceuticals, Inc. (SNOA) revenue, earnings & EPS growth — 3, 5 & 10-year CAGR
Revenue CAGR
10 Years0.31%
5 Years-4.44%
3 Years4.2%
TTM26.83%
Profit CAGR
10 Years-
5 Years-
3 Years-
TTM10.09%
EPS CAGR
10 Years-
5 Years-
3 Years-
TTM44.27%
Return on Capital
10 Years-63.36%
5 Years-38.83%
3 Years-37.24%
Last Year-35.99%
SNOA Peer Comparison
Sonoma Pharmaceuticals, Inc. (SNOA) competitors in Therapy-focused branded biopharma — business model, growth, and fundamentals comparison
| Company | Market Cap | Stock Price | P/E Ratio (TTM) | Revenue Growth 1Y | Net Margin | Return on Equity (ROE) | FCF Yield | Debt / Equity |
|---|---|---|---|---|---|---|---|---|
 SSKN | 6.66M | 0.18 | -0.67 | 0.61% | -35.64% | -8.4% | 3.31 | |
 DERM | 102.16M | 5.00 | -6.94 | -29.11% | -15.49% | -45.4% | 1.28 | |
 PRPH | 4.98M | 0.12 | -0.05 | -84.75% | -38.72% | -6.08% | 3.34 | |
 CLSD | 2.15M | 0.41 | -0.06 | -79.77% | -7.81% | |||
 BRTX | 1.8M | 0.23 | -0.19 | 175.03% | -33.05% | -5.74% | ||
 PAVM | 466.18M | 7.14 | 14.39 | 22.15% | -217914.55% | -245.07% | ||
 MTNB | 3.85M | 0.65 | -0.13 | -100% | -270.65% | 0.38 | ||
 MCK | 92.15B | 752.30 | 29.25 | 16.22% | 1.18% | 301.44% |
Compare SNOA vs Peers
Sonoma Pharmaceuticals, Inc. (SNOA) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.
SNOA Income Statement
Sonoma Pharmaceuticals, Inc. (SNOA) annual income statement — 10-year revenue, gross profit & net income history
10Y historyFree accessUpdated daily
| Line item | Mar'17 | Mar'18 | Mar'19 | Mar'20 | Mar'21 | Mar'22 | Mar'23 | Mar'24 | Mar'25 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|
| Sales/Revenue | 12.82M | 16.66M | 18.97M | 17.93M | 18.63M | 12.63M | 13.27M | 12.73M | 14.29M | 17.72M |
| Revenue Growth % | 36.89% | 29.89% | 13.88% | -5.49% | 3.91% | -32.21% | 5.1% | -4.05% | 12.19% | 26.83% |
| Cost of Goods Sold | 7.16M | 9.35M | 10.09M | 9.81M | 12.07M | 8.63M | 8.79M | 7.99M | 8.82M | 10.96M |
| COGS % of Revenue | 55.81% | 56.12% | 53.19% | 54.7% | 64.79% | 68.38% | 66.27% | 62.74% | 61.75% | - |
| Gross Profit | 5.67M▲ 0% | 7.31M▲ 29.0% | 8.88M▲ 21.5% | 8.12M▼ 8.5% | 6.56M▼ 19.2% | 3.99M▼ 39.1% | 4.48M▲ 12.1% | 4.75M▲ 6.0% | 5.46M▲ 15.2% | 6.76M▲ 0% |
| Gross Margin % | 44.19% | 43.88% | 46.81% | 45.3% | 35.21% | 31.62% | 33.73% | 37.26% | 38.25% | 38.16% |
| Gross Profit Growth % | 114.05% | 28.97% | 21.48% | -8.54% | -19.24% | -39.12% | 12.12% | 5.99% | 15.17% | - |
| Operating Expenses | 18.64M | 21.5M | 20.14M | 15.51M | 10.01M | 9.88M | 9.05M | 9.45M | 9.18M | 9.53M |
| OpEx % of Revenue | 145.36% | 129.06% | 106.16% | 86.52% | 53.72% | 78.24% | 68.17% | 74.17% | 64.21% | - |
| Selling, General & Admin | 17.07M | 19.92M | 18.62M | 14.17M | 9.45M | 9.76M | 8.84M | 7.58M | 7.36M | 7.39M |
| SG&A % of Revenue | 133.07% | 119.61% | 98.16% | 79.06% | 50.74% | 77.25% | 66.61% | 59.48% | 51.52% | - |
| Research & Development | 1.58M | 1.57M | 1.52M | 1.34M | 555K | 125K | 207K | 1.87M | 1.81M | 2.14M |
| R&D % of Revenue | 12.29% | 9.45% | 8% | 7.47% | 2.98% | 0.99% | 1.56% | 14.69% | 12.7% | - |
| Other Operating Expenses | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Operating Income | -12.97M▲ 0% | -14.19M▼ 9.4% | -11.26M▲ 20.7% | -7.39M▲ 34.4% | -3.45M▲ 53.3% | -5.89M▼ 70.7% | -4.57M▲ 22.4% | -4.7M▼ 2.9% | -3.71M▲ 21.1% | -2.77M▲ 0% |
| Operating Margin % | -101.16% | -85.18% | -59.35% | -41.22% | -18.51% | -46.62% | -34.43% | -36.91% | -25.97% | -15.61% |
| Operating Income Growth % | 11.83% | -9.36% | 20.66% | 34.36% | 53.33% | -70.69% | 22.37% | -2.87% | 21.08% | - |
| EBITDA | -12.73M | -13.7M | -10.8M | -7.08M | -3.22M | -5.7M | -4.45M | -4.53M | -3.57M | -2.66M |
| EBITDA Margin % | -99.23% | -82.24% | -56.96% | -39.48% | -17.3% | -45.15% | -33.49% | -35.53% | -25% | -15.03% |
| EBITDA Growth % | 12.05% | -7.65% | 21.13% | 34.49% | 54.48% | -76.94% | 22.03% | -1.8% | 21.06% | 38.29% |
| D&A (Non-Cash Add-back) | 248K | 490K | 453K | 312K | 227K | 186K | 125K | 176K | 138K | 103K |
| EBIT | -12.93M | -14.24M | -11.31M | -3.53M | -3.45M | -5.89M | -4.57M | -4.7M | -3.71M | -2.48M |
| Net Interest Income | 19K | 218K | 157K | 34K | 4K | -10K | 16K | 0 | 0 | 0 |
| Interest Income | 22K | 258K | 190K | 50K | 16K | 0 | 16K | 0 | 0 | 0 |
| Interest Expense | 3K | 40K | 33K | 16K | 12K | 10K | 0 | 0 | 0 | 0 |
| Other Income/Expense | 37K | -89K | -82K | 3.85M | -453K | 469K | -614K | -330K | 803K | -684K |
| Pretax Income | -12.94M▲ 0% | -14.28M▼ 10.4% | -11.34M▲ 20.6% | -3.54M▲ 68.7% | -3.9M▼ 10.1% | -5.42M▼ 38.9% | -5.18M▲ 4.3% | -5.03M▲ 3.0% | -2.91M▲ 42.2% | -3.45M▲ 0% |
| Pretax Margin % | -100.87% | -85.71% | -59.78% | -19.77% | -20.95% | -42.9% | -39.06% | -39.51% | -20.35% | -19.47% |
| Income Tax | -4.27M | 50K | 458K | 29K | 713K | -332K | -33K | -196K | 550K | 180K |
| Effective Tax Rate % | 32.99% | -0.35% | -4.04% | -0.82% | -18.27% | 6.13% | 0.64% | 3.9% | -18.92% | -5.22% |
| Net Income | 9.27M▲ 0% | -14.33M▼ 254.5% | -11.8M▲ 17.7% | -3.31M▲ 72.0% | -3.95M▼ 19.4% | -5.09M▼ 28.8% | -5.15M▼ 1.3% | -4.83M▲ 6.1% | -3.46M▲ 28.5% | -3.37M▲ 0% |
| Net Margin % | 72.31% | -86.01% | -62.19% | -18.45% | -21.2% | -40.28% | -38.81% | -37.97% | -24.2% | -19.02% |
| Net Income Growth % | 191.26% | -254.5% | 17.66% | 71.96% | -19.41% | -28.76% | -1.28% | 6.13% | 28.5% | 10.09% |
| Net Income (Continuing) | -8.67M | -14.33M | -11.8M | -3.57M | -4.62M | -5.09M | -5.15M | -4.83M | -3.46M | -2.55M |
| Discontinued Operations | 17.94M | 0 | 0 | 265K | 665K | 0 | 0 | 0 | 0 | 0 |
| Minority Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| EPS (Diluted) | -221.70▲ 0% | -284.66▼ 28.4% | -127.68▲ 55.1% | -22.40▲ 82.5% | -23.65▼ 5.6% | -19.17▲ 18.9% | -15.18▲ 20.8% | -5.32▲ 65.0% | -2.79▲ 47.6% | -1.97▲ 0% |
| EPS Growth % | -88.18% | -28.4% | 55.15% | 82.46% | -5.58% | 18.94% | 20.81% | 64.95% | 47.56% | 44.27% |
| EPS (Basic) | -221.70 | -284.66 | -127.68 | -22.40 | -23.65 | -19.17 | -15.18 | -5.32 | -2.79 | - |
| Diluted Shares Outstanding | 46.93K | 50.33K | 92.4K | 147.7K | 199.6K | 265.3K | 339.4K | 909K | 1.24M | 1.71M |
| Basic Shares Outstanding | 46.93K | 50.33K | 92.4K | 147.7K | 199.6K | 265.3K | 339.4K | 909K | 1.24M | 1.71M |
| Dividend Payout Ratio | - | - | - | - | - | - | - | - | - | - |
SNOA Balance Sheet
Sonoma Pharmaceuticals, Inc. (SNOA) balance sheet — assets, liabilities & shareholders' equity
| Line item | Mar'17 | Mar'18 | Mar'19 | Mar'20 | Mar'21 | Mar'22 | Mar'23 | Mar'24 | Mar'25 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|
| Total Current Assets | 22.64M | 16.25M | 12.5M | 12.38M | 12.98M | 16.43M | 13.8M | 12.55M | 12.65M | 12.14M |
| Cash & Short-Term Investments | 17.46M | 10.07M | 3.69M | 3.69M | 4.22M | 7.4M | 3.82M | 3.13M | 5.37M | 2.56M |
| Cash Only | 17.46M | 10.07M | 3.69M | 3.69M | 4.22M | 7.4M | 3.82M | 3.13M | 5.37M | 2.56M |
| Short-Term Investments | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Accounts Receivable | 2.11M | 1.54M | 3.48M | 3.97M | 2.81M | 2.41M | 2.57M | 5.99M | 3.76M | 2.38M |
| Days Sales Outstanding | 59.99 | 33.68 | 66.98 | 80.89 | 54.98 | 69.57 | 70.73 | 171.8 | 96.13 | 58.96 |
| Inventory | 2.22M | 2.87M | 3.41M | 2.19M | 2.53M | 2.66M | 2.86M | 2.72M | 2.92M | 3.7M |
| Days Inventory Outstanding | 113.27 | 111.87 | 123.32 | 81.59 | 76.51 | 112.56 | 118.61 | 124.21 | 120.59 | 117.01 |
| Other Current Assets | 237K | 239K | 223K | 271K | 209K | 218K | 240K | 367K | 360K | 3.5M |
| Total Non-Current Assets | 2.82M | 2.95M | 1.95M | 2.18M | 2M | 2.42M | 2.43M | 2.19M | 1.04M | 1.48M |
| Property, Plant & Equipment | 1.24M | 1.14M | 727K | 1.33M | 1.13M | 879K | 906K | 651K | 309K | 956K |
| Fixed Asset Turnover | 10.35x | 14.66x | 26.09x | 13.50x | 16.50x | 14.37x | 14.65x | 19.56x | 46.24x | 24.74x |
| Goodwill | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Intangible Assets | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Long-Term Investments | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Non-Current Assets | 1.58M | 1.82M | 1.23M | 850K | 875K | 707K | 578K | 396K | 147K | 399K |
| Total Assets | 25.46M▲ 0% | 19.21M▼ 24.6% | 14.45M▼ 24.8% | 14.56M▲ 0.8% | 14.99M▲ 2.9% | 18.84M▲ 25.7% | 16.23M▼ 13.9% | 14.74M▼ 9.2% | 13.69M▼ 7.1% | 13.62M▲ 0% |
| Asset Turnover | 0.50x | 0.87x | 1.31x | 1.23x | 1.24x | 0.67x | 0.82x | 0.86x | 1.04x | 1.27x |
| Asset Growth % | 84.45% | -24.56% | -24.77% | 0.78% | 2.93% | 25.74% | -13.87% | -9.19% | -7.1% | 0.55% |
| Total Current Liabilities | 3.29M | 3.26M | 3.59M | 4.73M | 4.08M | 5.82M | 3.72M | 3.72M | 4.1M | 4.22M |
| Accounts Payable | 1.25M | 1.27M | 1.25M | 2.07M | 1.77M | 1.64M | 841K | 607K | 953K | 1.65M |
| Days Payables Outstanding | 64 | 49.67 | 45.4 | 76.94 | 53.49 | 69.36 | 34.9 | 27.73 | 39.42 | 50.36 |
| Short-Term Debt | 123K | 230K | 322K | 481K | 596K | 808K | 431K | 323K | 220K | 146K |
| Deferred Revenue (Current) | 521K | 206K | 102K | 273K | 319K | 1.28M | 160K | 478K | 641K | 2.44M |
| Other Current Liabilities | 0 | 589K | 814K | 0 | 367K | 784K | 566K | 694K | 487K | 3.76M |
| Current Ratio | 6.89x | 4.98x | 3.48x | 2.62x | 3.18x | 2.82x | 3.71x | 3.37x | 3.09x | 3.09x |
| Quick Ratio | 6.21x | 4.11x | 2.53x | 2.16x | 2.56x | 2.37x | 2.94x | 2.64x | 2.38x | 2.38x |
| Cash Conversion Cycle | 109.26 | 95.88 | 144.9 | 85.54 | 77.99 | 112.77 | 154.44 | 268.28 | 177.3 | 125.6 |
| Total Non-Current Liabilities | 740K | 619K | 368K | 4.21M | 5.55M | 4.33M | 4.54M | 4.88M | 5.19M | 5.97M |
| Long-Term Debt | 45K | 32K | 12K | 0 | 1.31M | 0 | 0 | 0 | 0 | 509K |
| Capital Lease Obligations | 168K | 144K | 0 | 235K | 529K | 309K | 162K | 87K | 27K | 858K |
| Deferred Tax Liabilities | -168K | -144K | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Non-Current Liabilities | 0 | 144K | 0 | 3.73M | 3.48M | 3.84M | 4.24M | 4.71M | 5.14M | 20.82M |
| Total Liabilities | 4.03M | 3.88M | 3.96M | 8.94M | 9.62M | 10.15M | 8.25M | 8.6M | 9.28M | 10.19M |
| Total Debt | 410K | 553K | 475K | 850K | 2.67M | 1.37M | 849K | 608K | 305K | 655K |
| Net Debt | -17.05M | -9.51M | -3.21M | -2.84M | -1.54M | -6.03M | -2.97M | -2.52M | -5.07M | -1.91M |
| Debt / Equity | 0.02x | 0.04x | 0.05x | 0.15x | 0.50x | 0.16x | 0.11x | 0.10x | 0.07x | 0.07x |
| Debt / EBITDA | - | - | - | - | - | - | - | - | - | -0.25x |
| Net Debt / EBITDA | - | - | - | - | - | - | - | - | - | 0.72x |
| Interest Coverage | -4324.67x | -354.73x | -341.15x | -461.88x | -287.42x | -588.70x | - | - | - | - |
| Total Equity | 21.43M▲ 0% | 15.33M▼ 28.5% | 10.49M▼ 31.6% | 5.62M▼ 46.4% | 5.36M▼ 4.6% | 8.7M▲ 62.2% | 7.98M▼ 8.3% | 6.14M▼ 23.1% | 4.41M▼ 28.1% | 3.43M▲ 0% |
| Equity Growth % | 111.35% | -28.49% | -31.56% | -46.38% | -4.64% | 62.17% | -8.28% | -23.07% | -28.12% | -105.37% |
| Book Value per Share | 456.64 | 304.50 | 113.52 | 38.08 | 26.87 | 32.78 | 23.50 | 6.75 | 3.55 | 2.00 |
| Total Shareholders' Equity | 21.43M | 15.33M | 10.49M | 5.62M | 5.36M | 8.7M | 7.98M | 6.14M | 4.41M | 3.43M |
| Common Stock | 1K | 1K | 2K | 2K | 2K | 2K | 5K | 2K | 0 | 0 |
| Retained Earnings | -143.1M | -157.44M | -169.24M | -175.33M | -179.28M | -184.36M | -189.51M | -194.35M | -197.81M | -200.4M |
| Treasury Stock | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Accumulated OCI | -4.18M | -3.98M | -4.35M | -5.61M | -4.58M | -4.31M | -3.42M | -2.72M | -4.38M | -3.19M |
| Minority Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
SNOA Cash Flow Statement
Sonoma Pharmaceuticals, Inc. (SNOA) cash flow — operating, investing & free cash flow history
| Line item | Mar'17 | Mar'18 | Mar'19 | Mar'20 | Mar'21 | Mar'22 | Mar'23 | Mar'24 | Mar'25 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash from Operations | -8.17M | -12.44M | -11.72M | -4.59M | -3.38M | -4.25M | -6.15M | -2.4M | -88K | -88K |
| Operating CF Margin % | -63.68% | -74.67% | -61.77% | -25.61% | -18.13% | -33.64% | -46.35% | -18.83% | -0.62% | - |
| Operating CF Growth % | 6.62% | -52.31% | 5.8% | 60.82% | 26.42% | -25.75% | -44.82% | 61.02% | 96.33% | -444.43% |
| Net Income | 9.27M | -14.33M | -11.8M | -3.31M | -3.95M | -5.09M | -5.15M | -4.83M | -3.46M | -3.37M |
| Depreciation & Amortization | 248K | 490K | 453K | 312K | 227K | 186K | 125K | 176K | 138K | 139K |
| Stock-Based Compensation | 2.15M | 2.41M | 1.64M | 839K | 371K | 382K | 669K | 516K | 224K | 133K |
| Deferred Taxes | -4.27M | 651K | 0 | 0 | -1.41M | -829K | -37K | -109K | 357K | 181K |
| Other Non-Cash Items | -15.31M | 90K | -741K | -773K | 4K | -2.03M | 106K | 161K | 174K | -1.25M |
| Working Capital Changes | -257K | -1.75M | -1.27M | -1.66M | 1.38M | 3.13M | -1.86M | 1.69M | 2.48M | 1.47M |
| Change in Receivables | 34K | 11K | -1.16M | -2.19M | 2.61M | 1.97M | 62K | -230K | 434K | 692K |
| Change in Inventory | -675K | -583K | -779K | 323K | -65K | -100K | 44K | 184K | -388K | -793K |
| Change in Payables | -58K | 9K | 5K | 336K | -796K | -157K | -864K | -278K | 416K | 1.23M |
| Cash from Investing | 18.22M | -201K | -131K | 3.64M | 388K | -99K | -258K | -2K | -80K | -165K |
| Capital Expenditures | -394K | -187K | -100K | -206K | -179K | -137K | -269K | -17K | -80K | -165K |
| CapEx % of Revenue | 3.07% | 1.12% | 0.53% | 1.15% | 0.96% | 1.08% | 2.03% | 0.13% | 0.56% | - |
| Acquisitions | 18.64M | 0 | 0 | 2.7M | 0 | 0 | 0 | 0 | 0 | 0 |
| Investments | - | - | - | - | - | - | - | - | - | - |
| Other Investing | -21K | -14K | -31K | 1.15M | 567K | 38K | 11K | 15K | 0 | 0 |
| Cash from Financing | -32K | 5.24M | 5.49M | 1.03M | 3.31M | 7.4M | 2.49M | 1.68M | 3.03M | 798K |
| Debt Issued (Net) | -130K | -280K | -478K | -347K | 1.02M | -374K | -120K | -481K | -404K | -244K |
| Equity Issued (Net) | 0 | 1000K | 1000K | 1000K | 1000K | 1000K | 1000K | 1000K | 1000K | 833K |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Share Repurchases | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | -1K | 0 |
| Other Financing | 98K | 52K | 0 | 0 | 0 | 216K | -259K | 373K | 356K | 209K |
| Net Change in Cash | 9.99M▲ 0% | -7.39M▼ 174.0% | -6.38M▲ 13.8% | 2K▲ 100.0% | 529K▲ 26350.0% | 3.18M▲ 500.4% | -3.58M▼ 212.6% | -692K▲ 80.6% | 2.25M▲ 424.6% | -3.29M▲ 0% |
| Free Cash Flow | -8.56M▲ 0% | -12.63M▼ 47.5% | -11.82M▲ 6.4% | -4.8M▲ 59.4% | -3.56M▲ 25.8% | -4.38M▼ 23.3% | -6.42M▼ 46.4% | -2.42M▲ 62.4% | -168K▲ 93.0% | -3.01M▲ 0% |
| FCF Margin % | -66.75% | -75.8% | -62.29% | -26.76% | -19.09% | -34.72% | -48.38% | -18.96% | -1.18% | -17.01% |
| FCF Growth % | 5.83% | -47.48% | 6.41% | 59.41% | 25.85% | -23.28% | -46.43% | 62.39% | 93.04% | -2743.4% |
| FCF per Share | -182.41 | -250.85 | -127.89 | -32.48 | -17.82 | -16.53 | -18.92 | -2.66 | -0.14 | -0.14 |
| FCF Conversion (FCF/Net Income) | -0.88x | 0.87x | 0.99x | 1.39x | 0.86x | 0.84x | 1.19x | 0.50x | 0.03x | 0.89x |
| Interest Paid | 0 | 0 | 0 | 16K | 12K | 24K | 0 | 0 | 11K | 3K |
| Taxes Paid | 0 | 0 | 0 | 0 | 941K | 767K | 0 | 0 | 0 | 0 |
SNOA Key Ratios
Sonoma Pharmaceuticals, Inc. (SNOA) financial ratios — P/E, ROE, debt and 30+ core market and balance-sheet ratios
| Metric | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|
| Return on Equity (ROE) | 58.75% | -77.96% | -91.4% | -41.06% | -71.9% | -72.35% | -61.78% | -68.51% | -65.55% | -98.19% |
| Return on Invested Capital (ROIC) | -271.61% | -208.81% | -129.03% | -110.21% | -78.37% | -136.15% | -89.33% | -81.78% | -188.07% | -188.07% |
| Gross Margin | 44.19% | 43.88% | 46.81% | 45.3% | 35.21% | 31.62% | 33.73% | 37.26% | 38.25% | 38.16% |
| Net Margin | 72.31% | -86.01% | -62.19% | -18.45% | -21.2% | -40.28% | -38.81% | -37.97% | -24.2% | -19.02% |
| Debt / Equity | 0.02x | 0.04x | 0.05x | 0.15x | 0.50x | 0.16x | 0.11x | 0.10x | 0.07x | 0.07x |
| Interest Coverage | -4324.67x | -354.73x | -341.15x | -461.88x | -287.42x | -588.70x | - | - | - | - |
| FCF Conversion | -0.88x | 0.87x | 0.99x | 1.39x | 0.86x | 0.84x | 1.19x | 0.50x | 0.03x | 0.89x |
| Revenue Growth | 36.89% | 29.89% | 13.88% | -5.49% | 3.91% | -32.21% | 5.1% | -4.05% | 12.19% | 26.83% |
SNOA Frequently Asked Questions
Sonoma Pharmaceuticals, Inc. (SNOA) stock FAQ — growth, dividends, profitability & financials explained
Growth & Financials
Sonoma Pharmaceuticals, Inc. (SNOA) reported $17.7M in revenue for fiscal year 2025. This represents a 1207% increase from $1.4M in 2005.
Sonoma Pharmaceuticals, Inc. (SNOA) grew revenue by 12.2% over the past year. This is steady growth.
Sonoma Pharmaceuticals, Inc. (SNOA) reported a net loss of $3.4M for fiscal year 2025.
Dividend & Returns
Sonoma Pharmaceuticals, Inc. (SNOA) has a return on equity (ROE) of -65.5%. Negative ROE indicates the company is unprofitable.
Sonoma Pharmaceuticals, Inc. (SNOA) had negative free cash flow of $3.0M in fiscal year 2025, likely due to heavy capital investments.
Explore More SNOA
Sonoma Pharmaceuticals, Inc. (SNOA) financial analysis — history, returns, DCA and operating performance tools
Total Return Calculator
Historical returns with dividends reinvested
DCA Calculator
Dollar cost averaging vs lump sum
Dividend History
Yield, growth, payout safety & DRIP
Earnings History
EPS trends, net income & profitability
Price History
Long-term charts & historical price data
Revenue History
Sales growth patterns & revenue breakdown
Financial Ratios
30 years of market, efficiency and balance-sheet ratios
Valuation
DCF intrinsic value, peer multiples & estimates